Figure 7.
Figure 7. Regression of lymphoma xenografts after PRIT comparing anti-CD20 1F5 (scFv)4SA fusion protein and 1F5 Ab-SA chemical conjugate. Athymic BALB/c mice bearing Ramos lymphoma xenografts were injected intraperitoneally with either 1.4 (⋄) or 2.8 (○) nM 1F5 (scFv)4SA or 1F5 Ab-SA (▪), followed 20 hours later by 5.8 nM CA, and 4 hours after that with (A) 800 or (B) 1200 μCi (29.6 or 44.4 MBq, respectively) 90Y-DOTA-biotin. Control mice bearing xenograft tumors were treated with pretargeted CC49 (scFv)4SA (□). Tumor volume curves though day 60 incorporate the tumor size determined at the time of euthanasia.

Regression of lymphoma xenografts after PRIT comparing anti-CD20 1F5 (scFv)4SA fusion protein and 1F5 Ab-SA chemical conjugate. Athymic BALB/c mice bearing Ramos lymphoma xenografts were injected intraperitoneally with either 1.4 (⋄) or 2.8 (○) nM 1F5 (scFv)4SA or 1F5 Ab-SA (▪), followed 20 hours later by 5.8 nM CA, and 4 hours after that with (A) 800 or (B) 1200 μCi (29.6 or 44.4 MBq, respectively) 90Y-DOTA-biotin. Control mice bearing xenograft tumors were treated with pretargeted CC49 (scFv)4SA (□). Tumor volume curves though day 60 incorporate the tumor size determined at the time of euthanasia.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal